Related references
Note: Only part of the references are listed.Agomelatine in the Treatment of Major Depressive Disorder Potential for Clinical Effectiveness
Sidney H. Kennedy et al.
CNS DRUGS (2010)
Safety Reporting and Adverse-Event Profile of Mirtazapine Described in Randomized Controlled Trials in Comparison with Other Classes of Antidepressants in the Acute-Phase Treatment of Adults with Depression Systematic Review and Meta-Analysis
Norio Watanabe et al.
CNS DRUGS (2010)
Rethinking depression and the actions of antidepressants: Uncovering the links between the neural and behavioral elements
Martin M. Katz et al.
JOURNAL OF AFFECTIVE DISORDERS (2010)
Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder: A Randomized, Double-Blind Comparison With Sertraline
Siegfried Kasper et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
George I. Papakostas et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
Guy M. Goodwin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
Armin Szegedi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Sleep disturbances: Core symptoms of major depressive disorder rather than associated or comorbid disorders
Julien Mendlewicz
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2009)
Antidepressants and their onset of action: A major clinical, methodological and pronostical issue
D. Gourion
ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE (2008)
Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis
Norio Watanabe et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Addressing circadian rhythm disturbances in depressed patients
RW Lam
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine
Patrick Lemoine et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Early onset of selective serotonin reuptake inhibitor antidepressant action - Systematic review and meta-analysis
Matthew J. Taylor et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data
Alan D. Lopez et al.
LANCET (2006)
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder
GI Papakostas et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
Placebo-controlled trial of agomelatine in the treatment of major depressive disorder
SH Kennedy et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2006)
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice
MH Trivedi et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Agomelatine - A preliminary review of a new antidepressant
Michael Zupancic et al.
CNS DRUGS (2006)
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo
C Shelton et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients
A Farabaugh et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Is there a delay in the antidepressant effect? A meta-analysis
MA Posternak et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties:: role of 5-HT2C receptor blockade
MJ Millan et al.
PSYCHOPHARMACOLOGY (2005)
Antidepressants and sleep - A qualitative review of the literature
S Wilson et al.
DRUGS (2005)
Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression
MM Katz et al.
NEUROPSYCHOPHARMACOLOGY (2004)
The economic burden of depression in the United States: How did it change between 1990 and 2000?
PE Greenberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways
MJ Millan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression
A Szegedi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)